Journal of Neurology

, Volume 255, Issue 2, pp 255–264 | Cite as

Cognitive impairment in 873 patients with idiopathic Parkinson's disease

Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD)
  • O. Riedel
  • J. Klotsche
  • A. Spottke
  • G. Deuschl
  • H. Förstl
  • F. Henn
  • I. Heuser
  • W. Oertel
  • H. Reichmann
  • P. Riederer
  • C. Trenkwalder
  • R. Dodel
  • H.-U. Wittchen
ORIGINAL COMMUNICATION

Abstract

Background

Parkinson's disease (PD) is often accompanied by non-motor complications, such as dementia, depression, and psychotic symptoms, which worsen the prognosis and increase the personal and socioeconomic burden of disease. Prevalence estimates of these complications are quite variable and are lacking for the outpatient care sector.

Methods

As part of a larger, nationwide, cross-sectional epidemiological study in n = 315 neurological outpatient settings in Germany, this paper estimates the frequency of dementia and cognitive impairment in n = 873 outpatients meeting the UK Brain Bank criteria for idiopathic PD. Assessments were based on a clinical interview and neuropsychological assessments, including the Hoehn & Yahr rating and Unified Parkinson's Disease Rating Scale (UPDRS). Cognitive impairment was assessed by the Mini-Mental State Exam (MMSE), Clock Drawing Test (CDT) and the Parkinson Neuropsychometric Dementia Assessment (PANDA) and the clinician's diagnosis of dementia was based on the diagnostic criteria of DSMIV.

Results

Using standardized cutoff scores, the prevalence of cognitive impairment in the study sample as measured by various methods was 17.5% by MMSE (≤ 24), 41.8% by CDT (≥ 3), 43.6% by PANDA (≤ 14), and 28.6% met the DSM-IV criteria for dementia. All estimates increased with age and PD severity. Gender was an inconsistent contributor while illness duration had no significant impact on cognition. Multiple regression analyses revealed PD severity to be the strongest predictor of dementia risk (OR = 4.3; 95% CI: 2.1–9.1), while neuropsychiatric syndromes had independent, although modest additional contributions (OR = 2.5, 95% CI: 1.6–3.8).

Conclusion

Estimates of cognitive impairment and dementia in PD patients are largely dependent on the diagnostic measure used. Using established clinical diagnostic standards for dementia the overall rate on routine outpatient neurological care is 28.6%, but using more sensitive neuropsychological measures, rates for cognitive impairment might be up to 2-fold higher. The MMSE revealed strikingly low sensitivity. Neuropsychiatric syndromes, in addition to PD severity and age, have an independent – although modest – additional contribution to patients' risk for cognitive impairment and dementia.

Key words

Parkinson's disease dementia cognitive impairment MMSE CDT PANDA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Soerensen P (2003) Prevalence and Characteristics of Dementia in Parkinson's Disease – An 8-Year Prospective Study. Arch Neurol 60:387–392PubMedCrossRefGoogle Scholar
  2. 2.
    Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Soerensen P (2001) Risk of dementia in Parkinson's disease: A community-based, prospective study. Neurology 56:730–736PubMedGoogle Scholar
  3. 3.
    Aarsland D, Larsen JP, Lim NG, Janvin C, Karlsen K, Tandberg E, Cummings J (1999) Range of neuropsychiatric disturbances in patients with Parkinson's disease. J Neurol Neurosurg Ps 67:492–496Google Scholar
  4. 4.
    Adler C (2005) Nonmotor Complications in Parkinson's Disease. Movement Disord 20:S23–S29PubMedCrossRefGoogle Scholar
  5. 5.
    American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders – Text revision. American Psychiatric Association, Washington, DCGoogle Scholar
  6. 6.
    Campenhausen S, Bornschein B, Wick R, Bötzel K, Sampaio C, Poewe W, Oleson J, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharm 15:473–490CrossRefGoogle Scholar
  7. 7.
    Cormack F, Aarsland D, Ballard C, Tovee M (2004) Pentagon drawing and neuropsychological performance in Dementia with Lewy bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. Int J Geriatr Psych 19:371–377CrossRefGoogle Scholar
  8. 8.
    Efron B, Tibshirani R (1993) An introduction to the bootstrap. Chapman and Hall, LondonGoogle Scholar
  9. 9.
    Emre M (2003) What causes mental dysfunction in Parkinson's disease? Movement Disord 18:63–71CrossRefGoogle Scholar
  10. 10.
    Fahn S (1987) Unified Parkinson's Disease Rating Scale. In: Fahn S, Calne D (eds) Recent Developments in Parkinson's Disease. MacMillan Healthcare Information, Florham Park, NJ, pp 153–163Google Scholar
  11. 11.
    Folstein M, Folstein S, McHugh P (1975) Mini-Mental state: a practical method for grading the mental state of patients by the clinician. J Psychiatr Res 12:189–198PubMedCrossRefGoogle Scholar
  12. 12.
    Hobson P, Meara J (2004) Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Movement Disord 19:1043–1049PubMedCrossRefGoogle Scholar
  13. 13.
    Hoehn M, Yahr M (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442PubMedGoogle Scholar
  14. 14.
    Hughes A, Daniel S, Kilford L, Lees A (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Ps 55:181–184Google Scholar
  15. 15.
    Hughes T, Ross H, Musa S, Bhattacherjee S, Nathan R, Mindham R, Spokes E (2000) A 10-year-study of the incidence of and factors predicting dementia in Parkinson's disease. Neurology 54:1596–1603PubMedGoogle Scholar
  16. 16.
    Huse D, Schulman K, Orsini L, Castelli- Haley J, Kennedy S, Lenhart G (2005) Burden of illness in Parkinson's disease. Movement Disord 20:1449–1454PubMedCrossRefGoogle Scholar
  17. 17.
    Kalbe E, Calabrese P, Kohn N, Hilker R, Riedel O, Wittchen HU, Dodel R, Otto J, Ebersbach G, Kessler J (2007) Screening for cognitive deficits in Parkinson's Disease with the Neuropsychometric Dementia Assessment (PANDA) instrument. Parkinsonism Relat D (in press)Google Scholar
  18. 18.
    Kalbe E, Riedel O, Kohn N, Dodel R, Calabrese P, Kessler J (2007) Sensitivitat und Spezifitat des "Parkinson Neuropsychometric Dementia Assessment" (PANDA): Ergebnisse der GEPAD-Studie. Aktuel Neurol 34:140–146CrossRefGoogle Scholar
  19. 19.
    Klockgether T (2004) Parkinson's disease: clinical aspects. Cell Tissue Res 318:115–120PubMedCrossRefGoogle Scholar
  20. 20.
    Leentjens A, Verhey F, Lousberg R, Spitsbergen H, Wilmink F (2000) The validity of the Hamilton and Montgomery- Asberg Depression Rating Scales as screening and diagnostic tools for depression in Parkinson's disease. Int J Geriatr Psych 15:644–649CrossRefGoogle Scholar
  21. 21.
    Louis E, Schupf N, Manly J, Marder K, Tang M-X, Mayeux R (2005) Association between mild parkinsonian signs in mild cognitive impairment in a community. Neurology 64:1157–1161PubMedGoogle Scholar
  22. 22.
    Miyasaki J, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K, Shulman L, Gronseth G, Weiner WJ (2006) Practice Parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Neurology 66:996–1002PubMedCrossRefGoogle Scholar
  23. 23.
    Montgomery S, Asberg M (1979) A new depression scale, designed to be sensitive to change. Brit J Psychiat 134:382–389PubMedCrossRefGoogle Scholar
  24. 24.
    Muslimovic D, Post B, Speelman J, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65:1239–1245PubMedCrossRefGoogle Scholar
  25. 25.
    National Institute of Mental Health (1976) CGI: Clinical Global Impressions. National Institute of Mental Health, Chevy Chase, MDGoogle Scholar
  26. 26.
    Nishiwaki Y, Breeze E, Smeeth L, Bulpitt C, Peters R, Fletcher A (2004) Validity of the Clock-Drawing-Test as a screening tool for cognitive impairment in the elderly. Am J Epidemiol 160:797–807PubMedCrossRefGoogle Scholar
  27. 27.
    Noe E, Marder K, Bell K, Jacobs D, Manly J, Stern Y (2004) Comparison of dementia with Lewy bodies to Alzheimer's disease and Parkinson's disease with dementia. Movement Disord 19:60–67PubMedCrossRefGoogle Scholar
  28. 28.
    Riedel O, Dodel R, Spottke A, Deuschl G, Forstl H, Henn F, Heuser I, Oertel W, Reichmann H, Riederer P, Trenkwalder C, Wittchen H-U (2006) Wie beurteilen Arzte die Haufigkeit demenzieller, depressiver und psychotischer Symptome bei Patienten mit der Parkinson- Krankheit? Eine Befragung von 500 Facharzten im ambulanten Versorgungssektor Deutschlands. Aktuel Neurol 33:374–380CrossRefGoogle Scholar
  29. 29.
    Royall RM (1986) Model robust confidence intervals using maximum likelihood estimators. Int Stat Rev 54:221–226CrossRefGoogle Scholar
  30. 30.
    Schrag A, Jahanshahi M, Quinn N (2001) What contributes to depression in Parkinson's disease? Psychol Med 31:65–73PubMedCrossRefGoogle Scholar
  31. 31.
    Seigerschmidt E, Mosch E, Siemen M, Forstl H, Bickel H (2002) The clock drawing test and questionable dementia: reliability and validity. Int J Geriatr Ps 17:1048–1054CrossRefGoogle Scholar
  32. 32.
    Shulman K (2000) Clock-drawing: Is it the ideal cognitive screening test? Int J Geriatr Ps 15:548–561CrossRefGoogle Scholar
  33. 33.
    Vingerhoets G, Verleden S, Santens P, Miatton M, De Reuck J (2003) Predictors of cognitive impairment in advanced Parkinson's disease. J Neurol Neurosurg Ps 74:793–796CrossRefGoogle Scholar
  34. 34.
    Wichowicz H, Slawek J, Derejko M, Cubala W (2006) Factors associated with depression in Parkinson's disease: a cross-sectional study in a Polish population. Eur Psychiat 21:516–520CrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2008

Authors and Affiliations

  • O. Riedel
    • 1
  • J. Klotsche
    • 1
  • A. Spottke
    • 2
  • G. Deuschl
    • 4
  • H. Förstl
    • 5
  • F. Henn
    • 6
  • I. Heuser
    • 7
  • W. Oertel
    • 3
  • H. Reichmann
    • 8
  • P. Riederer
    • 9
  • C. Trenkwalder
    • 10
  • R. Dodel
    • 3
  • H.-U. Wittchen
    • 1
  1. 1.Institute of Clinical Psychology and PsychotherapyTechnical University of DresdenDresdenGermany
  2. 2.Dept. of NeurologyFriedrich-Wilhelms-University BonnBonnGermany
  3. 3.Dept. of NeurologyPhilipps-University MarburgMarburgGermany
  4. 4.Dept. of NeurologyChristian-Albrechts-University KielKielGermany
  5. 5.Dept. of Psychiatry and PsychotherapyTechnical University of MunichMunichGermany
  6. 6.Brookhaven National LaboratoryNY UptonUSA
  7. 7.Charite-Campus-Benjamin FranklinUniversitatsmedizinBerlinGermany
  8. 8.Dept. of NeurologyFaculty of Medicine Carl Gustav CarusDresdenGermany
  9. 9.Dept. of Clinical NeurochemistryClinical Neurochemistry and NPF-Center of Excellence Laboratories UniversityWürzburgGermany
  10. 10.Paracelsus-Elena-ClinicKasselGermany

Personalised recommendations